Daiichi Sankyo at SABCS 2026

Dec 8–11, 2026 San Antonio, TX ~11k attendees Website

Daiichi Sankyo brings 1 presentation to SABCS 2026 in San Antonio, and exhibits at Booth 343. The drugmaker's poster describes real-world treatment patterns in high-risk HER2-positive early breast cancer in the United States.

OrganizationSABCS 2026 Attendance
Daiichi Sankyo
Tokyo, Japan
Pharma
Japanese drugmaker whose oncology portfolio centers on antibody-drug conjugates, including HER2- and TROP2-directed treatments used in breast cancer.
Booth
Exhibiting at Booth 343
Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Poster
Fri Dec 11
12:30–2pm
Real-world treatment patterns in patients with high-risk HER2+ eBC in the United States
Exhibit Hall
Real-World Data and Real-World Evidence

Explore the full SABCS 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full SABCS 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Daiichi Sankyo

Tell us what you sell and we’ll find the people at Daiichi Sankyo most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with the San Antonio Breast Cancer Symposium, UT Health San Antonio or the American Association for Cancer Research. Organization details are derived from SABCS’s published program and exhibitor list. Submit a correction